Abstract: The efficacy of chimeric antigen receptor T (CAR⁃T) cell therapy has been confirmed in the treatment of lymphoma, but challenges such as resistance, safety and adverse reactions impacted prognosis in some patients. Molecular targeted drugs can regulate the tumor microenvironment and enhance tumor⁃specific antigen expression, and help to reduce the occurrence of antigen escape. Some small molecule targeted drugs can induce tumor cell death by regulating the balance between anti⁃apoptotic and pro⁃apoptotic signaling pathways. Additionally, these drugs can also regulate the immune suppression and activation pathways to improve the anti⁃tumor efficacy of CAR⁃T cell therapy, reverse the exhaustion of CAR⁃T cell, and enhance their anti⁃tumor effects. The efficacy, safety, and mechanisms of action involved in combining molecular targeted drugs with CAR⁃ T cell therapy in lymphoma treatment have garnered increasing attention. In this paper, the research progress of the combination of CAR⁃ T cell therapy with commonly used molecular targeted drugs in the treatment of lymphoma was reviewed.

Key words: Lymphoma；CAR-T cell therapy, Molecular targeted anti?tumor drugs, Tumor microenvironment